Journal of the American Academy of Dermatology
Volume 60, Issue 6 , Pages 934-943, June 2009

Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis

  • Lawrence Anderson, MD, FACP

      Affiliations

    • Dermatology Associates of Tyler, Tyler, Texas
    • Corresponding Author InformationReprint requests: Lawrence Anderson, MD, FACP, 1367 Dominion Plaza, Tyler, TX 75703.
    • ,
  • George J. Schmieder, DO

      Affiliations

    • Park Avenue Dermatology, PA, Orange Park, Florida
    • ,
  • W. Philip Werschler, MD

      Affiliations

    • Premier Clinical Research, Spokane, Washington
    • ,
  • Eduardo H. Tschen, MD

      Affiliations

    • Academic Dermatology Associates, Albuquerque, New Mexico
    • ,
  • Mark R. Ling, MD, PhD

      Affiliations

    • MedaPhase, Inc., Newnan, Georgia
    • ,
  • Dow B. Stough, MD

      Affiliations

    • Burk Pharmaceutical Research, Hot Springs, Arkansas
    • ,
  • Janelle Katsamas

      Affiliations

    • Peplin Ltd, Brisbane, Australia

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Funding sources: Peplin Ltd, for Clinical Research and as a member of the Scientific Advisory Committee.

 Disclosure: Dr Anderson was a clinical investigator, chairs a dose escalation committee on an unrelated clinical trial, and serves on an advisory board for Peplin Ltd. Ms Katsamas is an employee of Peplin Ltd. Dr Ling received a research grant for clinical studies from Graceway and Actavis. Dr Schmieder served as an investigator for Peplin, Genentech, Novum, and Astellas. Dr Werschler has served as an investigator for Peplin, Graceway, and Valent/ICN and as an investigator, speaker, consultant, and on an advisory board for Dermik. Drs Stough and Tschen report no conflicts of interest.

 A list of all clinical investigators participating in the study is found at the end of the article.

PII: S0190-9622(09)00033-4

doi:10.1016/j.jaad.2009.01.008

Journal of the American Academy of Dermatology
Volume 60, Issue 6 , Pages 934-943, June 2009

Article Tools

* Image Usage & Resolution